Dicot Pharma outlines Phase 2b trial design for ED drug candidate LIB — 01
Dicot Pharma highlighted new data on its erectile-dysfunction candidate LIB-01 at the SMSNA conference. Results were already presented via three abstracts covering how the drug works, early clinical findings, and the planned mid-stage trial. Early clinical outcomes indicated meaningful, sustained improvements in erecti